Insider transactions

EDGAR

ZIMMER BIOMET HOLDINGS, INC.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-16.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
6 transactions, 17,341 shares
Sum of shares × price per share: 1,584,583.45

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–50 of 174

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-10-01 Filed 2026-10-05Campbell Gary Craig Officer: President, Americas
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)2,3680—2,368Direct (D) No— Open filing 0002155115-26-000003 Read from the filing’s XML Dispute this row
2026-10-01 Filed 2026-10-05Campbell Gary Craig Officer: President, Americas
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)93288.42
82,407.44

Derived: shares × price per share. Exact value 82407.44.

1,436Direct (D) No
F1
  • F1 Represents shares withheld by Zimmer Biomet Holdings, Inc. (the Company) to satisfy tax withholding obligations on the vesting of restricted stock units (RSUs).
Open filing 0002155115-26-000003 Read from the filing’s XML Dispute this row
2026-10-01 Filed 2026-10-05Campbell Gary Craig Officer: President, Americas
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)1,2180—2,654Direct (D) No— Open filing 0002155115-26-000003 Read from the filing’s XML Dispute this row
2026-10-01 Filed 2026-10-05Campbell Gary Craig Officer: President, Americas
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)48088.42
42,441.6

Derived: shares × price per share. Exact value 42441.60.

2,174Direct (D) No
F1
  • F1 Represents shares withheld by Zimmer Biomet Holdings, Inc. (the Company) to satisfy tax withholding obligations on the vesting of restricted stock units (RSUs).
Open filing 0002155115-26-000003 Read from the filing’s XML Dispute this row
2026-10-01 Filed 2026-10-05Campbell Gary Craig Officer: President, Americas
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (2,368)
Disposed (D)2,3680—0Direct (D) No
F2
  • F2 Each RSU represents a contingent right to receive one share of Company common stock.
Open filing 0002155115-26-000003 Read from the filing’s XML Dispute this row
2026-10-01 Filed 2026-10-05Campbell Gary Craig Officer: President, Americas
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (1,218)
Disposed (D)1,2180—2,434Direct (D) No
F2, F3
  • F2 Each RSU represents a contingent right to receive one share of Company common stock.
  • F3 One-third of these RSUs vested on October 1, 2026. The remaining RSUs vest one-half on October 1, 2027 and one-half on October 1, 2028.
Open filing 0002155115-26-000003 Read from the filing’s XML Dispute this row
2026-09-30 Filed 2026-10-02Farrell Michael J. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Phantom Stock Units — underlying Common Stock (417.363) — exercise price 89.85
Acquired (A)417.3630—20,073.731Direct (D) No
F1, F2, F3, F4
  • F1 The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors
  • F2 The Conversion or Exercise Price of Derivative Security is 1-for-1.
  • F3 Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director.
  • F4 Includes 49.652 phantom stock units accrued on July 31, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
Open filing 0001485164-26-000010 Read from the filing’s XML Dispute this row
2026-09-30 Filed 2026-10-02Kurdikar Devdatt Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Phantom Stock Units — underlying Common Stock (173.901) — exercise price 89.85
Acquired (A)173.9010—3,171.359Direct (D) No
F1, F2, F3, F4
  • F1 The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
  • F2 The Conversion or Exercise Price of Derivative Security is 1-for-1.
  • F3 Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director.
  • F4 Includes 7.276 phantom stock units accrued on July 31, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
Open filing 0001910621-26-000010 Read from the filing’s XML Dispute this row
2026-09-30 Filed 2026-10-02HIGGINS ARTHUR J Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Phantom Stock Units — underlying Common Stock (306.066) — exercise price 89.85
Acquired (A)306.0660—38,077.496Direct (D) No
F1, F2, F3, F4
  • F1 The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
  • F2 The Conversion or Exercise Price of Derivative Security is 1-for-1.
  • F3 Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs.
  • F4 Includes 96.739 phantom stock units accrued on July 31, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
Open filing 0001142083-26-000010 Read from the filing’s XML Dispute this row
2026-09-30 Filed 2026-10-02Hilado Maria Teresa Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Phantom Stock Units — underlying Common Stock (375.626) — exercise price 89.85
Acquired (A)375.6260—13,392.107Direct (D) No
F1, F2, F3, F4
  • F1 The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
  • F2 The Conversion or Exercise Price of Derivative Security is 1-for-1.
  • F3 Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs.
  • F4 Includes 32.614 phantom stock units accrued on July 31, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
Open filing 0001587868-26-000016 Read from the filing’s XML Dispute this row
2026-09-30 Filed 2026-10-02Shapiro Louis Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Phantom Stock Units — underlying Common Stock (153.033) — exercise price 89.85
Acquired (A)153.0330—3,865.311Direct (D) No
F1, F2, F3, F4
  • F1 The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
  • F2 The Conversion or Exercise Price of Derivative Security is 1-for-1.
  • F3 Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director.
  • F4 Includes 9.178 phantom stock units accrued on July 31, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
Open filing 0001999146-26-000010 Read from the filing’s XML Dispute this row
2026-09-30 Filed 2026-10-02Kolli Sreelakshmi Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Phantom Stock Units — underlying Common Stock (173.901) — exercise price 89.85
Acquired (A)173.9010—7,033.757Direct (D) No
F1, F2, F3, F4
  • F1 The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
  • F2 The Conversion or Exercise Price of Derivative Security is 1-for-1.
  • F3 Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director.
  • F4 Includes 17.252 phantom stock units accrued on July 31, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
Open filing 0001689392-26-000012 Read from the filing’s XML Dispute this row
2026-09-30 Filed 2026-10-02HAGEMANN ROBERT Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Phantom Stock Units — underlying Common Stock (306.066) — exercise price 89.85
Acquired (A)306.0660—33,660.840Direct (D) No
F1, F2, F3, F4
  • F1 The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
  • F2 The Conversion or Exercise Price of Derivative Security is 1-for-1.
  • F3 Units are to be settled in cash in five annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs.
  • F4 Includes 85.331 phantom stock units accrued on July 31, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
Open filing 0001222676-26-000012 Read from the filing’s XML Dispute this row
2026-09-11 Filed 2026-09-15Thornal Kevin R Officer: Grp Pres-Global Business
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)5,69192.95
528,978.45

Derived: shares × price per share. Exact value 528978.45.

0Direct (D) No— Open filing 0001783992-26-000006 Read from the filing’s XML Dispute this row
2026-09-04 Filed 2026-09-09Phipps Chad F Officer: See remarks below.
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)3,00098.35
295,050

Derived: shares × price per share. Exact value 295050.00.

65,231Direct (D) No
F1
  • F1 Includes 471 shares acquired under the Employee Stock Purchase Plan and pursuant to dividend reinvestment through July 31, 2026.
Open filing 0001346672-26-000010 Read from the filing’s XML Dispute this row
2026-08-03 Filed 2026-08-05Desai Chintan Officer: President, APAC
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (10,168)
Acquired (A)10,1680—10,168Direct (D) No
F1, F2
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock.
  • F2 One-third of the RSUs shall vest on each of August 3, 2027, August 3, 2028 and August 3, 2029.
Open filing 0002136215-26-000006 Read from the filing’s XML Dispute this row
2026-08-01 Filed 2026-08-04Thornal Kevin R Officer: Grp Pres-Global Business
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)9,9570—9,957Direct (D) No— Open filing 0001783992-26-000004 Read from the filing’s XML Dispute this row
2026-08-01 Filed 2026-08-04Thornal Kevin R Officer: Grp Pres-Global Business
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)4,26692.68
395,372.88

Derived: shares × price per share. Exact value 395372.88.

5,691Direct (D) No
F1
  • F1 Represents shares withheld by Zimmer Biomet Holdings, Inc. (the Company) to satisfy tax withholding obligations on the vesting of restricted stock units (RSUs).
Open filing 0001783992-26-000004 Read from the filing’s XML Dispute this row
2026-08-01 Filed 2026-08-04Thornal Kevin R Officer: Grp Pres-Global Business
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (9,957)
Disposed (D)9,9570—19,913Direct (D) No
F2, F3
  • F2 Each RSU represents a contingent right to receive one share of Company common stock.
  • F3 One-third of the RSUs vested on August 1, 2026. The remaining RSUs vest one-half on each of August 1, 2027 and August 1, 2028.
Open filing 0001783992-26-000004 Read from the filing’s XML Dispute this row
2026-06-30 Filed 2026-07-02HIGGINS ARTHUR J Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Phantom Stock Units — underlying Common Stock (317.369) — exercise price 86.65
Acquired (A)317.3690—37,674.691Direct (D) No
F1, F2, F3
  • F1 The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
  • F2 The Conversion or Exercise Price of Derivative Security is 1-for-1.
  • F3 Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs.
Open filing 0001142083-26-000008 Read from the filing’s XML Dispute this row
2026-06-30 Filed 2026-07-02HAGEMANN ROBERT Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Phantom Stock Units — underlying Common Stock (317.369) — exercise price 86.65
Acquired (A)317.3690—33,269.443Direct (D) No
F1, F2, F3
  • F1 The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
  • F2 The Conversion or Exercise Price of Derivative Security is 1-for-1.
  • F3 Units are to be settled in cash in five annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs.
Open filing 0001222676-26-000010 Read from the filing’s XML Dispute this row
2026-06-30 Filed 2026-07-02Kurdikar Devdatt Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Phantom Stock Units — underlying Common Stock (180.323) — exercise price 86.65
Acquired (A)180.3230—2,990.182Direct (D) No
F1, F2, F3
  • F1 The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
  • F2 The Conversion or Exercise Price of Derivative Security is 1-for-1.
  • F3 Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director.
Open filing 0001910621-26-000008 Read from the filing’s XML Dispute this row
2026-06-30 Filed 2026-07-02Shapiro Louis Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Phantom Stock Units — underlying Common Stock (158.684) — exercise price 86.65
Acquired (A)158.6840—3,703.100Direct (D) No
F1, F2, F3
  • F1 The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
  • F2 The Conversion or Exercise Price of Derivative Security is 1-for-1.
  • F3 Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director.
Open filing 0001999146-26-000008 Read from the filing’s XML Dispute this row
2026-06-30 Filed 2026-07-02Farrell Michael J. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Phantom Stock Units — underlying Common Stock (432.776) — exercise price 86.65
Acquired (A)432.7760—19,606.716Direct (D) No
F1, F2, F3
  • F1 The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
  • F2 The Conversion or Exercise Price of Derivative Security is 1-for-1.
  • F3 Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director.
Open filing 0001485164-26-000008 Read from the filing’s XML Dispute this row
2026-06-30 Filed 2026-07-02Kolli Sreelakshmi Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Phantom Stock Units — underlying Common Stock (180.323) — exercise price 86.65
Acquired (A)180.3230—6,842.604Direct (D) No
F1, F2, F3
  • F1 The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
  • F2 The Conversion or Exercise Price of Derivative Security is 1-for-1.
  • F3 Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director.
Open filing 0001689392-26-000010 Read from the filing’s XML Dispute this row
2026-06-30 Filed 2026-07-02Hilado Maria Teresa Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Phantom Stock Units — underlying Common Stock (389.498) — exercise price 86.65
Acquired (A)389.4980—12,983.867Direct (D) No
F1, F2, F3
  • F1 The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
  • F2 The Conversion or Exercise Price of Derivative Security is 1-for-1.
  • F3 Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs.
Open filing 0001587868-26-000012 Read from the filing’s XML Dispute this row
2026-06-01 Filed 2026-06-03Noor Jehanzeb Officer: See remarks below.
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (1,857)
Acquired (A)1,8570—1,857Direct (D) No
F1, F2
  • F1 Each RSU represents a contingent right to receive one share of Company common stock.
  • F2 Vests annually over three years in increments of one-third each year, commencing June 1, 2027.
Open filing 0002059755-26-000006 Read from the filing’s XML Dispute this row
2026-05-29 Filed 2026-06-02Yi Sang Officer: Group President, Asia Pacific
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)4,20082.64
347,088

Derived: shares × price per share. Exact value 347088.00.

28,051Direct (D) No— Open filing 0001635943-26-000013 Read from the filing’s XML Dispute this row
2026-05-29 Filed 2026-06-02Yi Sang Officer: Group President, Asia Pacific
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)80082.66
66,128

Derived: shares × price per share. Exact value 66128.00.

27,251Direct (D) No— Open filing 0001635943-26-000013 Read from the filing’s XML Dispute this row
2026-05-22 Filed 2026-05-27BERNARD BETSY J Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Phantom Stock Units — underlying Common Stock (875.35) — exercise price 85.68
Acquired (A)875.350—21,581.562Direct (D) No
F1, F2, F3, F4
  • F1 The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
  • F2 The Conversion or Exercise Price of Derivative Security is 1-for-1.
  • F3 Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director.
  • F4 Includes 60.604 phantom stock units accrued on April 30, 2026, 57.375 phantom stock units accrued on January 30, 2026, 49.323 phantom stock units accrued on October 31, 2025 and 53.221 phantom stock units accrued on July 31, 2025, in each case under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
Open filing 0001166854-26-000002 Read from the filing’s XML Dispute this row
2026-05-22 Filed 2026-05-27BERNARD BETSY J Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (1,517.274)
Acquired (A)1,517.2740—24,506Direct (D) No
F2, F5, F6
  • F2 The Conversion or Exercise Price of Derivative Security is 1-for-1.
  • F5 The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date.
  • F6 Includes Restricted Stock Units granted in prior years that are subject to different mandatory deferral periods.
Open filing 0001166854-26-000002 Read from the filing’s XML Dispute this row
2026-05-22 Filed 2026-05-27Jafry Syed A. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Phantom Stock Units — underlying Common Stock (875.35) — exercise price 85.68
Acquired (A)875.350—8,288.638Direct (D) No
F1, F2, F3, F4
  • F1 The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
  • F2 The Conversion or Exercise Price of Derivative Security is 1-for-1.
  • F3 Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director
  • F4 Includes 21.697 phantom stock units accrued on April 30, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
Open filing 0001745891-26-000004 Read from the filing’s XML Dispute this row
2026-05-22 Filed 2026-05-27Jafry Syed A. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (1,517.274)
Acquired (A)1,517.2740—9,098Direct (D) No
F2, F5, F6
  • F2 The Conversion or Exercise Price of Derivative Security is 1-for-1.
  • F5 The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date.
  • F6 Includes Restricted Stock Units granted in prior years that are subject to different mandatory deferral periods.
Open filing 0001745891-26-000004 Read from the filing’s XML Dispute this row
2026-05-22 Filed 2026-05-27Shapiro Louis Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Phantom Stock Units — underlying Common Stock (875.35) — exercise price 85.68
Acquired (A)875.350—3,544.416Direct (D) No
F1, F2, F3, F4
  • F1 The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
  • F2 The Conversion or Exercise Price of Derivative Security is 1-for-1.
  • F3 Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director.
  • F4 Includes 7.812 phantom stock units accrued on April 30, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
Open filing 0001999146-26-000006 Read from the filing’s XML Dispute this row
2026-05-22 Filed 2026-05-27Shapiro Louis Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (1,517.274)
Acquired (A)1,517.2740—3,991.063Direct (D) No
F2, F5, F6
  • F2 The Conversion or Exercise Price of Derivative Security is 1-for-1.
  • F5 The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date.
  • F6 Includes Restricted Stock Units granted in prior years that are subject to different mandatory deferral periods.
Open filing 0001999146-26-000006 Read from the filing’s XML Dispute this row
2026-05-22 Filed 2026-05-27HIGGINS ARTHUR J Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Phantom Stock Units — underlying Common Stock (875.35) — exercise price 85.68
Acquired (A)875.350—37,357.322Direct (D) No
F1, F2, F3, F4
  • F1 The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
  • F2 The Conversion or Exercise Price of Derivative Security is 1-for-1.
  • F3 Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director.
  • F4 Includes 106.777 phantom stock units accrued on April 30, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
Open filing 0001142083-26-000006 Read from the filing’s XML Dispute this row
2026-05-22 Filed 2026-05-27HIGGINS ARTHUR J Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (1,517.274)
Acquired (A)1,517.2740—26,382Direct (D) No
F2, F5, F6
  • F2 The Conversion or Exercise Price of Derivative Security is 1-for-1.
  • F5 The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date.
  • F6 Includes Restricted Stock Units granted in prior years that are subject to different mandatory deferral periods.
Open filing 0001142083-26-000006 Read from the filing’s XML Dispute this row
2026-05-22 Filed 2026-05-27Hilado Maria Teresa Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Phantom Stock Units — underlying Common Stock (875.35) — exercise price 85.68
Acquired (A)875.350—12,594.369Direct (D) No
F1, F2, F3, F4
  • F1 The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
  • F2 The Conversion or Exercise Price of Derivative Security is 1-for-1.
  • F3 Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director.
  • F4 Includes 34.300 phantom stock units accrued on April 30, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
Open filing 0001587868-26-000008 Read from the filing’s XML Dispute this row
2026-05-22 Filed 2026-05-27Hilado Maria Teresa Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (1,517.274)
Acquired (A)1,517.2740—9,098Direct (D) No
F2, F5, F6
  • F2 The Conversion or Exercise Price of Derivative Security is 1-for-1.
  • F5 The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as of a Director or (2) the date that is three years after the grant date.
  • F6 Includes Restricted Stock Units granted in prior years that are subject to different mandatory deferral periods.
Open filing 0001587868-26-000008 Read from the filing’s XML Dispute this row
2026-05-22 Filed 2026-05-27Kurdikar Devdatt Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Phantom Stock Units — underlying Common Stock (875.35) — exercise price 85.68
Acquired (A)875.350—2,809.859Direct (D) No
F1, F2, F3, F4
  • F1 The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
  • F2 The Conversion or Exercise Price of Derivative Security is 1-for-1.
  • F3 Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director.
  • F4 Includes 5.662 phantom stock units accrued on April 30, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
Open filing 0001910621-26-000006 Read from the filing’s XML Dispute this row
2026-05-22 Filed 2026-05-27Kurdikar Devdatt Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (1,517.274)
Acquired (A)1,517.2740—2,922.072Direct (D) No
F2, F5, F6
  • F2 The Conversion or Exercise Price of Derivative Security is 1-for-1.
  • F5 The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date.
  • F6 Includes Restricted Stock Units granted in prior years that are subject to different mandatory deferral periods.
Open filing 0001910621-26-000006 Read from the filing’s XML Dispute this row
2026-05-22 Filed 2026-05-27HAGEMANN ROBERT Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Phantom Stock Units — underlying Common Stock (875.35) — exercise price 85.68
Acquired (A)875.350—32,952.074Direct (D) No
F1, F2, F3, F4
  • F1 The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
  • F2 The Conversion or Exercise Price of Derivative Security is 1-for-1.
  • F3 Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director.
  • F4 Includes 93.883 phantom stock units accrued on April 30, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
Open filing 0001222676-26-000008 Read from the filing’s XML Dispute this row
2026-05-22 Filed 2026-05-27HAGEMANN ROBERT Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (1,517.274)
Acquired (A)1,517.2740—25,927Direct (D) No
F2, F5, F6
  • F2 The Conversion or Exercise Price of Derivative Security is 1-for-1.
  • F5 The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date.
  • F6 Includes Restricted Stock Units granted in prior years that are subject to different mandatory deferral periods.
Open filing 0001222676-26-000008 Read from the filing’s XML Dispute this row
2026-05-22 Filed 2026-05-27Kolli Sreelakshmi Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Phantom Stock Units — underlying Common Stock (875.35) — exercise price 85.68
Acquired (A)875.350—6,662.281Direct (D) No
F1, F2, F3, F4
  • F1 The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
  • F2 The Conversion or Exercise Price of Derivative Security is 1-for-1.
  • F3 Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director.
  • F4 Includes 16.937 phantom stock units accrued on April 30, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
Open filing 0001689392-26-000008 Read from the filing’s XML Dispute this row
2026-05-22 Filed 2026-05-27Kolli Sreelakshmi Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (1,517.274)
Acquired (A)1,517.2740—6,875Direct (D) No
F2, F5, F6
  • F2 The Conversion or Exercise Price of Derivative Security is 1-for-1.
  • F5 The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date.
  • F6 Includes Restricted Stock Units granted in prior years that are subject to different mandatory deferral periods.
Open filing 0001689392-26-000008 Read from the filing’s XML Dispute this row
2026-05-22 Filed 2026-05-27Farrell Michael J. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Phantom Stock Units — underlying Common Stock (875.35) — exercise price 85.68
Acquired (A)875.350—19,173.94Direct (D) No
F1, F2, F3, F4
  • F1 The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
  • F2 The Conversion or Exercise Price of Derivative Security is 1-for-1.
  • F3 Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director.
  • F4 Includes 53.557 phantom stock units accrued on April 30, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
Open filing 0001485164-26-000006 Read from the filing’s XML Dispute this row
2026-05-22 Filed 2026-05-27Farrell Michael J. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (1,517.274)
Acquired (A)1,517.2740—13,757Direct (D) No
F2, F5, F6
  • F2 The Conversion or Exercise Price of Derivative Security is 1-for-1.
  • F5 The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination as a Director or (2) the date that is three years after the grant date.
  • F6 Includes Restricted Stock Units granted in prior years that are subject to different mandatory deferral periods.
Open filing 0001485164-26-000006 Read from the filing’s XML Dispute this row
2026-05-01 Filed 2026-05-05Stellato Paul A Officer: VP, Controller, CAO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (9,232)
Acquired (A)9,2320—9,232Direct (D) No
F1, F2
  • F1 Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock.
  • F2 Vests annually over three years in increments of one-third each year, commencing on May 1, 2027.
Open filing 0001714585-26-000010 Read from the filing’s XML Dispute this row
2026-04-01 Filed 2026-04-03Noor Jehanzeb Officer: See remarks below.
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)6,6260—6,828Direct (D) No
F1
  • F1 Includes 202 shares acquired under the Employee Stock Purchase Plan on December 31, 2025.
Open filing 0002059755-26-000004 Read from the filing’s XML Dispute this row
2026-04-01 Filed 2026-04-03Noor Jehanzeb Officer: See remarks below.
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)1,67790.67
152,053.59

Derived: shares × price per share. Exact value 152053.59.

5,151Direct (D) No
F2
  • F2 Represents shares withheld by Zimmer Biomet Holdings, Inc. (the Company) to satisfy tax withholding on the vesting of restricted stock units (RSUs).
Open filing 0002059755-26-000004 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 7,211 filings read, the latest filed 2026-11-13. Prior quarter ending 2026-06-30: 9,150 filings read.

Showing 1–50 of 786

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
Dodge Cox 22,732,137 SH2,019,295,730 dollarsLower by 1,392,598 Prior quarter: 24,124,735Open filing 0001193125-26-460252 Filed 2026-11-13 Dispute this row
BlackRock, Inc. Partly reported under another manager15,612,396 SH1,386,849,120 dollarsLower by 2,451 Prior quarter: 15,614,847Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 12,479,866 SH1,108,586,497 dollarsLower by 155,071 Prior quarter: 12,634,937Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
Capital International Investors Partly reported under another manager10,859,352 SH964,636,238 dollarsLower by 1,324,262 Prior quarter: 12,183,614Open filing 0001562230-26-000136 Filed 2026-11-12 Dispute this row
STATE STREET CORP Partly reported under another manager8,883,451 SH791,212,240 dollarsHigher by 6,280 Prior quarter: 8,877,171Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
VANGUARD PORTFOLIO MANAGEMENT LLC 8,139,992 SH723,075,489 dollarsLower by 301,755 Prior quarter: 8,441,747Open filing 0002100121-26-001150 Filed 2026-11-13 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager5,387,130 SH476,711,117 dollarsHigher by 37,907 Prior quarter: 5,349,223Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
Invesco Ltd. Partly reported under another manager4,128,790 SH366,760,415 dollarsHigher by 148,930 Prior quarter: 3,979,860Open filing 0000914208-26-000462 Filed 2026-11-12 Dispute this row
PRIMECAP MANAGEMENT CO/CA/ 3,801,250 SH337,665,038 dollarsLower by 15,430 Prior quarter: 3,816,680Open filing 0000763212-26-000037 Filed 2026-11-12 Dispute this row
VAN ECK ASSOCIATES CORP Partly reported under another manager3,457,999 SH307,174,051 dollarsLower by 43,655 Prior quarter: 3,501,654Open filing 0000869178-26-000119 Filed 2026-11-13 Dispute this row
MORGAN STANLEY Partly reported under another manager2,728,545 SH242,376,920 dollarsHigher by 137,042 Prior quarter: 2,591,503Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP Partly reported under another manager2,413,367 SH214,379,391 dollarsHigher by 851,228 Prior quarter: 1,562,139Open filing 0001164508-26-000060 Filed 2026-11-13 Dispute this row
AMERICAN CENTURY COMPANIES INC Partly reported under another manager2,362,262 SH209,839,884 dollarsLower by 382,201 Prior quarter: 2,744,463Open filing 0000748054-26-000008 Filed 2026-11-12 Dispute this row
DIMENSIONAL FUND ADVISORS LP Partly reported under another manager1,800,316 SH159,960,055 dollarsLower by 157,997 Prior quarter: 1,958,313Open filing 0000354204-26-001096 Filed 2026-11-04 Dispute this row
EQUITY INVESTMENT CORP 1,776,758 SH157,829,413 dollarsHigher by 95,398 Prior quarter: 1,681,360Open filing 0001685771-26-000009 Filed 2026-11-04 Dispute this row
MANUFACTURERS LIFE INSURANCE COMPANY, THE Partly reported under another manager1,391,546 SH123,611,031 dollarsLower by 66,713 Prior quarter: 1,458,259Open filing 0001145443-26-000111 Filed 2026-11-13 Dispute this row
Thrivent Financial for Lutherans Partly reported under another manager1,257,306 SH111,686 dollarsHigher by 616 Prior quarter: 1,256,690Open filing 0001193125-26-449292 Filed 2026-11-05 Dispute this row
UBS Group AG Partly reported under another manager1,127,503 SH100,156,091 dollarsLower by 1,631,112 Prior quarter: 2,758,615Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
Bank of New York Mellon Corp Partly reported under another manager1,083,132 SH96,214,609 dollarsLower by 29,893 Prior quarter: 1,113,025Open filing 0001390777-26-000121 Filed 2026-11-05 Dispute this row
VANGUARD FIDUCIARY TRUST CO 1,077,125 SH95,681,014 dollarsLower by 9,045 Prior quarter: 1,086,170Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
VICTORY CAPITAL MANAGEMENT INC 989,067 SH87,858,830 dollarsLower by 161,658 Prior quarter: 1,150,725Open filing 0001040188-26-000051 Filed 2026-11-10 Dispute this row
Amundi Partly reported under another manager986,059 SH87,591,620 dollarsHigher by 266,780 Prior quarter: 719,279Open filing 0001172661-26-004884 Filed 2026-11-06 Dispute this row
DEUTSCHE BANK AG\ Partly reported under another manager954,049 SH84,748,173 dollarsHigher by 30,497 Prior quarter: 923,552Open filing 0000948046-26-000083 Filed 2026-11-06 Dispute this row
RAYMOND JAMES FINANCIAL INC Partly reported under another manager890,416 SH79,095,668 dollarsHigher by 24,246 Prior quarter: 866,170Open filing 0000720005-26-000081 Filed 2026-11-12 Dispute this row
Quantinno Capital Management LP 887,922 SH78,874,167 dollarsHigher by 165,783 Prior quarter: 722,139Open filing 0001759654-26-000011 Filed 2026-11-13 Dispute this row
JPMORGAN CHASE CO Partly reported under another manager821,627 SH75,047,642 dollarsHigher by 5,713 Prior quarter: 815,914Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
Sound Shore Management Inc /CT/ 785,385 SH69,765,750 dollarsLower by 9,217 Prior quarter: 794,602Open filing 0001193125-26-451148 Filed 2026-11-06 Dispute this row
Boston Partners Partly reported under another manager755,041 SH67,077,301 dollarsHigher by 45,839 Prior quarter: 709,202Open filing 0001386060-26-000054 Filed 2026-11-10 Dispute this row
THOMPSON SIEGEL WALMSLEY LLC Partly reported under another manager664,273 SH59,007 dollarsHigher by 30,985 Prior quarter: 633,288Open filing 0001008322-26-000012 Filed 2026-11-05 Dispute this row
Alberta Investment Management Corp 550,000 SH48,856,500 dollarsHigher by 252,106 Prior quarter: 297,894Open filing 0001123292-26-001506 Filed 2026-11-09 Dispute this row
FIRST TRUST ADVISORS LP 544,038 SH48,326,911 dollarsHigher by 148,154 Prior quarter: 395,884Open filing 0001445546-26-008622 Filed 2026-11-12 Dispute this row
Swiss National Bank 529,200 SH47,008,836 dollarsLower by 16,800 Prior quarter: 546,000Open filing 0001582202-26-000008 Filed 2026-11-12 Dispute this row
Mitsubishi UFJ Asset Management Co., Ltd. Partly reported under another manager508,507 SH45,170,677 dollarsHigher by 26,452 Prior quarter: 482,055Open filing 0001193125-26-447983 Filed 2026-11-05 Dispute this row
Boston Trust Walden Corp Partly reported under another manager499,389 SH44,360,725 dollarsLower by 18,724 Prior quarter: 518,113Open filing 0001534866-26-000010 Filed 2026-10-30 Dispute this row
RHUMBLINE ADVISERS 479,175 SH42,564,993 dollarsLower by 13,283 Prior quarter: 492,458Open filing 0001115418-26-000015 Filed 2026-11-10 Dispute this row
Vanguard Global Advisers, LLC 451,964 SH40,147,962 dollarsHigher by 7,348 Prior quarter: 444,616Open filing 0001811242-26-000017 Filed 2026-11-13 Dispute this row
Douglas Lane Associates, LLC 451,613 SH40,116,816 dollarsLower by 26,167 Prior quarter: 477,780Open filing 0001672594-26-000004 Filed 2026-10-09 Dispute this row
WILSEY ASSET MANAGEMENT INC Partly reported under another manager434,595 SH38,605,084 dollarsHigher by 12,728 Prior quarter: 421,867Open filing 0001598379-26-000005 Filed 2026-10-21 Dispute this row
VANGUARD ASSET MANAGEMENT, Ltd 414,528 SH36,822,522 dollarsHigher by 23,354 Prior quarter: 391,174Open filing 0001680208-26-000018 Filed 2026-11-13 Dispute this row
CAUSEWAY CAPITAL MANAGEMENT LLC 412,776 SH36,666,852 dollarsLower by 376,034 Prior quarter: 788,810Open filing 0000945621-26-001389 Filed 2026-11-13 Dispute this row
JANE STREET GROUP, LLC Partly reported under another manager407,160 SH36,168,023 dollarsHigher by 394,719 Prior quarter: 12,441Open filing 0001595888-26-000162 Filed 2026-11-12 Dispute this row
CITIGROUP INC Partly reported under another manager400,328 SH35,561,136 dollarsHigher by 141,346 Prior quarter: 258,982Open filing 0000831001-26-000052 Filed 2026-11-04 Dispute this row
Sumitomo Mitsui Trust Group, Inc. Partly reported under another manager398,121 SH35,365,088 dollarsLower by 46,412 Prior quarter: 444,533Open filing 0001214659-26-013361 Filed 2026-10-29 Dispute this row
Nuveen, LLC Partly reported under another manager395,636 SH35,144,352 dollarsLower by 79,291 Prior quarter: 474,927Open filing 0000930413-26-003284 Filed 2026-11-10 Dispute this row
LSV ASSET MANAGEMENT Partly reported under another manager391,651 SH34,790 dollarsHigher by 210,992 Prior quarter: 180,659Open filing 0001050470-26-000015 Filed 2026-11-06 Dispute this row
BNP PARIBAS FINANCIAL MARKETS Partly reported under another manager391,369 SH34,765,308 dollarsHigher by 5,786 Prior quarter: 385,583Open filing 0001166588-26-000012 Filed 2026-11-12 Dispute this row
Lido Advisors, LLC Partly reported under another manager357,951 SH31,797,009 dollarsHigher by 40,902 Prior quarter: 317,049Open filing 0001172661-26-004854 Filed 2026-11-04 Dispute this row
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM 305,353 SH27,124,507 dollarsLower by 6,249 Prior quarter: 311,602Open filing 0001081019-26-000023 Filed 2026-11-13 Dispute this row
BARCLAYS PLC Partly reported under another manager305,314 SH27,121,043 dollarsLower by 263,376 Prior quarter: 568,690Open filing 0000312069-26-000241 Filed 2026-11-06 Dispute this row
Minneapolis Portfolio Management Group, LLC Partly reported under another manager300,988 SH26,736,744 dollarsHigher by 8,189 Prior quarter: 292,799Open filing 0001437749-26-035920 Filed 2026-11-09 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • HARRIS ASSOCIATES L P 12,738,025 SH
  • PRICE T ROWE ASSOCIATES INC /MD/ 4,797,157 SH
  • CITADEL ADVISORS LLC 3,477,472 SH
  • HOTCHKIS WILEY CAPITAL MANAGEMENT LLC 2,761,429 SH
  • BANK OF AMERICA CORP /DE/ 2,177,724 SH
  • NORTHERN TRUST CORP 1,965,052 SH
  • NORGES BANK 1,587,431 SH
  • Legal General Group Plc 1,465,529 SH
  • UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC 1,457,553 SH
  • Vestal Point Capital, LP 1,400,000 SH
  • CHARLES SCHWAB INVESTMENT MANAGEMENT INC 1,377,103 SH
  • Sixth Street Partners Management Company, L.P. 1,377,103 SH
  • Holocene Advisors, LP 1,177,461 SH
  • AMERIPRISE FINANCIAL INC 1,040,975 SH
  • GOLDMAN SACHS GROUP INC 968,628 SH
  • TORONTO DOMINION BANK 947,731 SH
  • Woodline Partners LP 942,300 SH
  • Point72 Asset Management, L.P. 879,851 SH
  • Meridiem Capital Partners LP 638,555 SH
  • Schonfeld Strategic Advisors LLC 603,216 SH
  • Magellan Asset Management Ltd 570,409 SH
  • HSBC HOLDINGS PLC 413,195 SH
  • CANADA PENSION PLAN INVESTMENT BOARD 378,010 SH
  • AQR CAPITAL MANAGEMENT LLC 367,365 SH
  • California Public Employees Retirement System 358,906 SH
  • Defilade Capital Management, L.P. 317,426 SH
  • ENVESTNET ASSET MANAGEMENT INC 308,571 SH
  • ROYAL BANK OF CANADA 305,507 SH
  • CapitalatWork S.A. 297,000 SH
  • Parkman Healthcare Partners LLC 232,557 SH
  • NATIONAL BANK OF CANADA /FI/ 229,490 SH
  • MILLENNIUM MANAGEMENT LLC 222,065 SH
  • SG Americas Securities, LLC 217,818 SH
  • ALLIANCEBERNSTEIN L.P. 214,937 SH
  • MOORE CAPITAL MANAGEMENT, LP 198,642 SH
  • ST GERMAIN D J CO INC 182,059 SH
  • ExodusPoint Capital Management, LP 180,884 SH
  • Invenomic Capital Management LP 178,691 SH
  • WELLS FARGO COMPANY/MN 178,591 SH
  • ARMOR ADVISORS, L.L.C. 151,264 SH
  • STATE OF WISCONSIN INVESTMENT BOARD 143,529 SH
  • Sio Capital Management, LLC 131,445 SH
  • NOMURA ASSET MANAGEMENT INTERNATIONAL INC. 128,379 SH
  • Bellevue Group AG 126,707 SH
  • State of Tennessee, Department of Treasury 121,591 SH
  • Tredje AP-fonden 117,984 SH
  • SUSQUEHANNA INTERNATIONAL GROUP, LLP 114,400 SH
  • NEW YORK STATE COMMON RETIREMENT FUND 113,475 SH
  • CITADEL ADVISORS LLC 108,800 SH
  • Longaeva Partners L.P. 98,054 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Dodge Cox Common Stock12.524,124,73506/30/2026 Filed 2026-08-13SCHEDULE 13G/AAmendment 5Open filing 0001193125-26-349494 Dispute this row
Capital International Investors Common Stock6.412,438,366.0006/30/2026 Filed 2026-08-12SCHEDULE 13GOpen filing 0001562230-26-000118 Dispute this row
T. Rowe Price Associates, Inc. COMMON STOCK4.17,997,80603/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0000080255-26-000400 Dispute this row
Vanguard Capital Management Common Stock7.5414,767,52703/31/2026 Filed 2026-04-30SCHEDULE 13GOpen filing 0002100119-26-001289 Dispute this row
The Vanguard Group Common Stock0003/13/2026 Filed 2026-03-27SCHEDULE 13G/AAmendment 9Open filing 0000102909-26-002651 Dispute this row
HARRIS ASSOCIATES L P Common Stock, $0.01 par value6.212,264,703.0012/31/2025 Filed 2026-02-17SCHEDULE 13GOpen filing 0000813917-26-000021 Dispute this row
Harris Associates, Inc. Common Stock, $0.01 par value6.212,264,703.0012/31/2025 Filed 2026-02-17SCHEDULE 13GOpen filing 0000813917-26-000021 Dispute this row
Dodge Cox Common Stock11.222,097,46306/30/2025 Filed 2025-08-13SCHEDULE 13G/AAmendment 4Open filing 0000950170-25-108132 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,093,437 filings read, dated 2004-06-14 to 2026-11-13: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
20151
2016204,322
2017202,494
2018202,048
2019193,638
2020144,184
2021224,474
202240,015
2023199,811
2024186,415
2025235,520
2026254,737

Filings made before the SEC required XML are listed, not extracted.

Back to ZIMMER BIOMET HOLDINGS, INC.